Stryker ROE 2010-2024 | SYK
Current and historical return on equity (ROE) values for Stryker (SYK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Stryker ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2024-12-31 | $2.99B | $20.63B | 15.02% |
| 2024-09-30 | $3.59B | $20.15B | 18.49% |
| 2024-06-30 | $3.45B | $19.76B | 18.28% |
| 2024-03-31 | $3.36B | $19.17B | 18.41% |
| 2023-12-31 | $3.17B | $18.59B | 17.89% |
| 2023-09-30 | $2.59B | $17.91B | 15.03% |
| 2023-06-30 | $2.71B | $17.36B | 16.09% |
| 2023-03-31 | $2.63B | $16.90B | 16.01% |
| 2022-12-31 | $2.36B | $16.62B | 14.78% |
| 2022-09-30 | $2.46B | $16.46B | 15.84% |
| 2022-06-30 | $2.08B | $15.67B | 13.91% |
| 2022-03-31 | $2.02B | $15.05B | 13.92% |
| 2021-12-31 | $1.99B | $14.88B | 14.15% |
| 2021-09-30 | $1.90B | $14.18B | 13.92% |
| 2021-06-30 | $2.08B | $13.82B | 15.61% |
| 2021-03-31 | $1.41B | $13.50B | 10.76% |
| 2020-12-31 | $1.60B | $13.08B | 12.31% |
| 2020-09-30 | $1.76B | $12.99B | 13.60% |
| 2020-06-30 | $1.60B | $12.75B | 12.56% |
| 2020-03-31 | $2.16B | $13.12B | 17.25% |
| 2019-12-31 | $2.08B | $12.81B | 17.09% |
| 2019-09-30 | $3.43B | $12.32B | 28.74% |
| 2019-06-30 | $3.55B | $11.94B | 31.40% |
| 2019-03-31 | $3.52B | $11.69B | 32.96% |
| 2018-12-31 | $3.55B | $11.73B | 35.29% |
| 2018-09-30 | $1.24B | $9.86B | 12.83% |
| 2018-06-30 | $1.08B | $9.46B | 11.05% |
| 2018-03-31 | $1.02B | $9.22B | 10.28% |
| 2017-12-31 | $1.02B | $9.98B | 10.16% |
| 2017-09-30 | $1.78B | $10.43B | 17.92% |
| 2017-06-30 | $1.70B | $10.04B | 17.61% |
| 2017-03-31 | $1.69B | $9.70B | 17.93% |
| 2016-12-31 | $1.65B | $9.55B | 17.91% |
| 2016-09-30 | $1.66B | $9.33B | 18.56% |
| 2016-06-30 | $1.61B | $9.10B | 18.39% |
| 2016-03-31 | $1.62B | $8.81B | 18.85% |
| 2015-12-31 | $1.44B | $8.51B | 17.02% |
| 2015-09-30 | $1.18B | $8.48B | 13.89% |
| 2015-06-30 | $0.93B | $8.51B | 10.96% |
| 2015-03-31 | $0.67B | $8.32B | 7.75% |
| 2014-12-31 | $0.52B | $8.60B | 5.84% |
| 2014-09-30 | $0.64B | $8.62B | 7.17% |
| 2014-06-30 | $0.69B | $9.00B | 7.67% |
| 2014-03-31 | $0.77B | $9.06B | 8.71% |
| 2013-12-31 | $1.01B | $9.05B | 11.55% |
| 2013-09-30 | $0.89B | $8.74B | 10.35% |
| 2013-06-30 | $1.14B | $8.60B | 13.41% |
| 2013-03-31 | $1.25B | $8.46B | 15.01% |
| 2012-12-31 | $1.30B | $8.60B | 15.77% |
| 2012-09-30 | $1.43B | $8.36B | 17.85% |
| 2012-06-30 | $1.40B | $7.95B | 17.98% |
| 2012-03-31 | $1.39B | $8.02B | 17.89% |
| 2011-12-31 | $1.35B | $7.68B | 17.66% |
| 2011-09-30 | $1.24B | $7.56B | 16.54% |
| 2011-06-30 | $1.25B | $7.78B | 16.82% |
| 2011-03-31 | $1.26B | $7.45B | 17.55% |
| 2010-12-31 | $1.27B | $7.17B | 18.25% |
| 2010-09-30 | $1.28B | $7.31B | 18.80% |
| 2010-06-30 | $1.18B | $6.75B | 17.78% |
| 2010-03-31 | $1.15B | $6.67B | 17.82% |
| 2009-12-31 | $1.11B | $6.60B | 17.91% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $147.446B | $22.595B |
| Stryker Corporation is a medical device company operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg and Neurotechnology & Spine. Orthopaedic?products include implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg?products consists of surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment and reprocessed and remanufactured medical devices. Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.977B | 28.52 |
| Boston Scientific (BSX) | United States | $155.488B | 41.98 |
| EssilorLuxottica (ESLOY) | France | $140.780B | 0.00 |
| Medtronic (MDT) | Ireland | $112.764B | 16.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.084B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.818B | 29.12 |
| GE HealthCare Technologies (GEHC) | United States | $42.113B | 20.51 |
| Agilent Technologies (A) | United States | $39.025B | 25.86 |
| ResMed (RMD) | United States | $34.189B | 26.33 |
| Terumo (TRUMY) | Japan | $26.310B | 37.41 |
| Koninklijke Philips (PHG) | Netherlands | $23.527B | 16.80 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.630B | 12.95 |
| Insulet (PODD) | United States | $20.222B | 86.57 |
| Baxter (BAX) | United States | $17.074B | 12.34 |
| Sunny Optical Technology (SNPTF) | China | $11.331B | 0.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.245B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.513B | 35.65 |
| Bio-Rad Laboratories (BIO) | United States | $8.001B | 27.70 |
| Demant (WILYY) | Denmark | $7.946B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.621B | 13.06 |
| Prestige Consumer Healthcare (PBH) | United States | $4.200B | 20.05 |
| ICU Medical (ICUI) | United States | $3.995B | 38.03 |
| Envista Holdings (NVST) | United States | $3.693B | 29.38 |
| Perrigo (PRGO) | Ireland | $3.443B | 10.14 |
| Haemonetics (HAE) | United States | $3.188B | 15.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.989B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.921B | 19.69 |
| QuidelOrtho (QDEL) | United States | $2.760B | 23.18 |
| LeMaitre Vascular (LMAT) | United States | $2.269B | 55.15 |
| Neogen (NEOG) | United States | $2.178B | 25.10 |
| AtriCure (ATRC) | United States | $1.914B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.484B | 25.90 |
| InMode (INMD) | Israel | $1.320B | 11.03 |
| BioLife Solutions (BLFS) | United States | $1.276B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.180B | 8.43 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.997B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.938B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.930B | 14.27 |
| Evolus (EOLS) | United States | $0.926B | 0.00 |
| CeriBell (CBLL) | United States | $0.828B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.689B | 0.00 |
| Valneva SE (VALN) | France | $0.643B | 0.00 |
| Omeros (OMER) | United States | $0.557B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.529B | 22.95 |
| Owens & Minor (OMI) | United States | $0.494B | 3.86 |
| Surmodics (SRDX) | United States | $0.492B | 0.00 |
| SNDL (SNDL) | Canada | $0.462B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.459B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.373B | 0.00 |
| ZimVie (ZIMV) | United States | $0.368B | 30.98 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.349B | 0.00 |
| Cerus (CERS) | United States | $0.323B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.321B | 58.60 |
| Viemed Healthcare (VMD) | United States | $0.310B | 29.52 |
| Sanara MedTech (SMTI) | United States | $0.309B | 0.00 |
| Quanterix (QTRX) | United States | $0.292B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Biote (BTMD) | United States | $0.260B | 5.69 |
| Canopy Growth (CGC) | Canada | $0.250B | 0.00 |
| Zynex (ZYXI) | United States | $0.236B | 49.40 |
| Sanuwave Health (SNWV) | United States | $0.231B | 3.24 |
| Brainsway (BWAY) | Israel | $0.212B | 112.80 |
| High Tide (HITI) | Canada | $0.209B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.206B | 15.39 |
| MacroGenics (MGNX) | United States | $0.181B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.174B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.163B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.140B | 17.51 |
| Jin Medical (ZJYL) | China | $0.124B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.112B | 0.00 |
| Fonar (FONR) | United States | $0.091B | 12.79 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| InterCure (INCR) | Israel | $0.075B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.067B | 0.00 |
| Exagen (XGN) | United States | $0.067B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.063B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.058B | 30.00 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Hongchang (HCIL) | China | $0.051B | 0.00 |
| MariMed (MRMD) | United States | $0.050B | 0.00 |
| United-Guardian (UG) | United States | $0.050B | 14.22 |
| ImmuCell (ICCC) | United States | $0.045B | 0.00 |
| Modular Medical (MODD) | United States | $0.044B | 0.00 |
| INLIF (INLF) | $0.040B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.031B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |